IL309789A - Semaglutide storage systems and their use - Google Patents
Semaglutide storage systems and their useInfo
- Publication number
- IL309789A IL309789A IL309789A IL30978923A IL309789A IL 309789 A IL309789 A IL 309789A IL 309789 A IL309789 A IL 309789A IL 30978923 A IL30978923 A IL 30978923A IL 309789 A IL309789 A IL 309789A
- Authority
- IL
- Israel
- Prior art keywords
- long
- pharmaceutical composition
- parenteral pharmaceutical
- acting parenteral
- semaglutide
- Prior art date
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims 19
- 229950011186 semaglutide Drugs 0.000 title claims 19
- 108010060325 semaglutide Proteins 0.000 title claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 239000011859 microparticle Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 239000008346 aqueous phase Substances 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000012071 phase Substances 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 229920001610 polycaprolactone Polymers 0.000 claims 4
- 239000008181 tonicity modifier Substances 0.000 claims 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 230000000704 physical effect Effects 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 239000007762 w/o emulsion Substances 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218405P | 2021-07-05 | 2021-07-05 | |
| US17/534,533 US11865213B2 (en) | 2021-07-05 | 2021-11-24 | Semaglutide depot systems and use thereof |
| PCT/IL2022/050708 WO2023281495A1 (en) | 2021-07-05 | 2022-07-04 | Semaglutide depot systems and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309789A true IL309789A (en) | 2024-02-01 |
Family
ID=84801375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309789A IL309789A (en) | 2021-07-05 | 2022-07-04 | Semaglutide storage systems and their use |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11865213B2 (https=) |
| EP (1) | EP4366759A4 (https=) |
| JP (1) | JP2024526279A (https=) |
| AU (1) | AU2022308705A1 (https=) |
| CA (1) | CA3220567A1 (https=) |
| IL (1) | IL309789A (https=) |
| MX (1) | MX2024000050A (https=) |
| WO (1) | WO2023281495A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| NL2036269B1 (en) | 2023-11-14 | 2025-05-23 | Nanomi B V | Peptide microparticle compositions and related methods |
| KR102930984B1 (ko) * | 2024-01-29 | 2026-02-25 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| WO2025229403A1 (en) * | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
| CN121015560B (zh) * | 2025-10-30 | 2026-01-30 | 上海银诺医药技术有限公司 | 依苏帕格鲁肽α纳米冻干胶束及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021531A2 (en) * | 2006-08-17 | 2008-02-21 | University Of Massachusetts | Stabilized emulsions, methods of preparation, and related reduced fat foods |
| TWI362947B (en) * | 2007-03-08 | 2012-05-01 | Univ Kaohsiung Medical | Controlled release pharmaceutical composition and manufacture method thereof |
| HUE060304T2 (hu) | 2010-01-04 | 2023-02-28 | Mapi Pharma Ltd | Glatiramer acetátot tartalmazó depó rendszer |
| EP2866825B1 (en) * | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| BR112016022550B1 (pt) * | 2014-03-31 | 2023-03-28 | Pharmathen S.A | Processo para a preparação de microesferas de plga de acetato de octreotida |
| CN105963257B (zh) * | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| CN105963258B (zh) * | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CA3040906A1 (en) * | 2016-10-20 | 2018-04-26 | Peptron, Inc. | Methods of delivering a neuroprotective polypeptide to the central nervous system |
| US20190380967A1 (en) | 2017-01-23 | 2019-12-19 | Savior Lifetec Corporation | Preparation of microparticles of an active ingredient |
| KR102047983B1 (ko) | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
| CN110101846B (zh) | 2018-02-01 | 2022-09-23 | 齐鲁制药有限公司 | 一种低突释率的索玛鲁肽微球及其制备方法 |
| US20210162013A1 (en) | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| US20220183964A1 (en) | 2019-04-11 | 2022-06-16 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled, sustained release of therapeutic agents |
| JP7336813B2 (ja) | 2019-07-29 | 2023-09-01 | ペプトロン インコーポレイテッド | レボドパ誘発性ジスキネジアの治療または進行抑制用の薬学組成物 |
| CN113018277B (zh) * | 2019-12-25 | 2023-10-31 | 丽珠医药集团股份有限公司 | 注射用缓释制剂及其制备方法 |
| CN115484935A (zh) | 2020-02-14 | 2022-12-16 | G2G生物公司 | 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物 |
| WO2022003662A1 (en) * | 2020-06-29 | 2022-01-06 | Mapi Pharma Ltd. | Low burst-release liraglutide depot systems |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| AU2023234747A1 (en) * | 2022-03-17 | 2024-09-12 | Mapi Pharma Ltd. | Depot systems comprising cariprazine or salts thereof |
-
2021
- 2021-11-24 US US17/534,533 patent/US11865213B2/en active Active
-
2022
- 2022-07-04 JP JP2023581040A patent/JP2024526279A/ja active Pending
- 2022-07-04 IL IL309789A patent/IL309789A/en unknown
- 2022-07-04 WO PCT/IL2022/050708 patent/WO2023281495A1/en not_active Ceased
- 2022-07-04 AU AU2022308705A patent/AU2022308705A1/en active Pending
- 2022-07-04 MX MX2024000050A patent/MX2024000050A/es unknown
- 2022-07-04 EP EP22835557.4A patent/EP4366759A4/en active Pending
- 2022-07-04 CA CA3220567A patent/CA3220567A1/en active Pending
-
2023
- 2023-12-19 US US18/544,721 patent/US20240148653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024526279A (ja) | 2024-07-17 |
| CA3220567A1 (en) | 2023-01-12 |
| WO2023281495A1 (en) | 2023-01-12 |
| MX2024000050A (es) | 2024-03-08 |
| US20240148653A1 (en) | 2024-05-09 |
| EP4366759A1 (en) | 2024-05-15 |
| US20230014750A1 (en) | 2023-01-19 |
| US11865213B2 (en) | 2024-01-09 |
| EP4366759A4 (en) | 2025-04-09 |
| AU2022308705A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309789A (en) | Semaglutide storage systems and their use | |
| JP2024526279A5 (https=) | ||
| DE60128261T3 (de) | Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln | |
| KR101892745B1 (ko) | 코어/셀 구조를 가진 미소구 | |
| CN104248623B (zh) | 使用非水性载体的持续释放制剂 | |
| KR102752744B1 (ko) | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 | |
| EP2327397A2 (en) | Method for manufacturing sustained release microsphere by solvent flow evaporation method | |
| DE102017106216A1 (de) | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung | |
| KR20240063866A (ko) | 결정-연관 및 비-결정-연관 급성 관절염의 치료에 사용하기 위한 콜히친을 포함하는 관절내 주사를 위한 투여 형태 | |
| KR102639578B1 (ko) | 주사 가능한 장기-지속형 날트렉손 마이크로입자 조성물 | |
| KR20250134143A (ko) | 골관절염과 같은 관절 질환의 치료에서 사용하기 위한 콜키신을 포함하는 관절내 주사용 제형 | |
| Li et al. | In vitro and in vivo studies of cyclosporin A-loaded microspheres based on copolymers of lactide and ɛ-caprolactone: Comparison with conventional PLGA microspheres | |
| US10987402B2 (en) | Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use | |
| KR20050093236A (ko) | 난용성 약물 함유 서방성 미세입자 및 그 제조방법 | |
| JP2024091835A (ja) | 持続性ブピバカインマイクロスフェア製剤 | |
| US20250319028A1 (en) | Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use | |
| WO2021053171A1 (de) | Extrudierte depotform mit kontrollierter wirkstofffreisetzung | |
| US12514908B2 (en) | Semaglutide depot systems and use thereof | |
| EP4721726A1 (en) | Pharmaceutical composition comprising glp-1 receptor agonist, gip/glp-1 receptor agonist and/or glp-1/gip/gcg receptor triple agonist | |
| EP4360619A1 (en) | Dosage form for intra-articular injection comprising colchicine and an anesthesic agent in the treatment of crystal-and non-crystal associated acute inflammatory arthritis | |
| HK40104581A (zh) | 包含他克莫司的药物制剂、其制备方法和用途 | |
| ONGED | i, United States Patent (10) Patent No.: US 9.023. 388 B2 |